Literature DB >> 1974502

Influence of carvedilol and propranolol on coronary blood flow.

H Sievert1, G Frey, R Schräder, T Schmidt, R van der Does, M Kaltenbach, G Kober.   

Abstract

A total of 17 patients with angiographically proven coronary artery disease and at least one stenosis blocking greater than or equal to 70% of the left anterior descending or circumflex artery were included in a double-blind, randomized study. They received either 5 mg carvedilol or 6 mg propranolol intravenously. Heart rate, aortic pressure, mean coronary sinus pressure and coronary flow (thermodilution) were measured and coronary resistance and the rate-pressure product were calculated before and 25 min after injection. Carvedilol significantly (P less than 0.05) lowered the heart rate (mean, 76 to 69 beats/min), aortic pressure (mean, 153/80-135/72 mm Hg), rate-pressure product (mean, 117-93 mm Hg/min), and coronary flow (mean, 114-94 ml/min). Coronary resistance (mean, 0.97-1.07 mm Hg x min/ml) and coronary flow related to the rate-pressure product (mean, 1.0-1.02 ml/mm Hg) showed no significant change after carvedilol treatment. Propranolol lowered the heart rate (mean, 76-64/min; P less than 0.05) and rate-pressure product (mean, 109-96 mm Hg/min; not significant). Aortic pressure (mean, 145/72-147/74 mm Hg), coronary flow (mean 109-101 ml/min), coronary resistance (mean, 1.1-1.2 mm Hg x min/ml), and coronary flow related to the rate-pressure product (mean, 1.12-1.19 ml/mm Hg) showed no significant change after propranolol administration. Following single application, carvedilol lowered the rate-pressure product more markedly than did propranolol on account of its acute blood-pressure-lowering effect. No differences in the hemodynamic effects of carvedilol and propranolol were found. Neither drug seems to influence the adaption of coronary flow to myocardial oxygen demand.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974502     DOI: 10.1007/bf01409480

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Propranolol in the treatment of acute myocardial infarction. Effect on myocardial oxygenation and hemodynamics.

Authors:  H S Mueller; S M Ayres; A Religa; R G Evans
Journal:  Circulation       Date:  1974-06       Impact factor: 29.690

2.  Measurement of coronary sinus blood flow by continuous thermodilution in man.

Authors:  W Ganz; K Tamura; H S Marcus; R Donoso; S Yoshida; H J Swan
Journal:  Circulation       Date:  1971-08       Impact factor: 29.690

3.  Canine myocardial adenosine and lactate production, oxygen consumption, and coronary blood flow during stellate ganglia stimulation.

Authors:  W L Miller; L Belardinelli; A Bacchus; D H Foley; R Rubio; R M Berne
Journal:  Circ Res       Date:  1979-12       Impact factor: 17.367

4.  Effect of propranolol, a beta-adrenergic antagonist, on blood flow in the coronary and other vascular fields.

Authors:  W G Nayler; I McInnes; J B Swann; V Carson; T E Lowe
Journal:  Am Heart J       Date:  1967-02       Impact factor: 4.749

5.  Consistent parallel relationships among myocardial oxygen consumption, coronary blood flow, and pericardial infusate adenosine concentration with various interventions and beta-blockade in the dog.

Authors:  R M Knabb; S W Ely; A N Bacchus; R Rubio; R M Berne
Journal:  Circ Res       Date:  1983-07       Impact factor: 17.367

6.  Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.

Authors:  T Wendt; R van der Does; R Schräder; H Landgraf; G Kober
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.

Authors:  G Sponer; W Bartsch; K Strein; B Müller-Beckmann; E Böhm
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

  7 in total
  5 in total

Review 1.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

3.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992

4.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

Review 5.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.